Related Experiment Video

Updated: Apr 12, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

8.4K

The BCL-2 protein family, BH3-mimetics and cancer therapy

A R D Delbridge1, A Strasser1

  • 11] The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia [2] Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.

Cell Death and Differentiation
|May 9, 2015
PubMed

Insights

Cancer cells evade apoptosis, leading to chemo-resistance. BH3-mimetic drugs offer a novel therapeutic strategy by directly activating apoptosis, bypassing common cancer resistance mechanisms.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Pharmacology

Background:

  • The BCL-2-regulated intrinsic apoptotic pathway is crucial for cancer cell survival and chemo-resistance.
  • Dysregulation of BCL-2 family proteins, including loss of pro-apoptotic members and overexpression of pro-survival members, contributes to tumorigenesis.
  • Many current cancer therapies rely on activating this pathway, but mutations in initiators like p53 cause treatment resistance.

Purpose of the Study:

  • To review the role of the BCL-2 protein family in cancer development and treatment.
  • To discuss mechanistic insights from mouse models of cancer.
  • To describe the development and therapeutic potential of BH3-mimetic drugs.

Main Methods:

  • Review of existing literature on the BCL-2 family in cancer.
  • Analysis of mechanistic studies utilizing mouse cancer models.
  • Examination of the development and preclinical/clinical data of BH3-mimetics.

Main Results:

  • Pro-apoptotic BCL-2 members show tumor-suppressive activity and are often lost in human cancers.
  • Pro-survival BCL-2 members promote cancer development.
  • BH3-mimetics directly activate apoptosis by inhibiting anti-apoptotic BCL-2 proteins, bypassing upstream resistance mechanisms.

Conclusions:

  • The BCL-2 family plays a critical role in cancer biology and therapeutic response.
  • BH3-mimetics represent a promising new class of cancer therapeutics by overcoming resistance to apoptosis.
  • Targeting the BCL-2 pathway offers a viable strategy for treating cancers refractory to conventional therapies.

More Related Videos

Identifying Protein-protein Interaction Sites Using Peptide Arrays07:44

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

18.8K
Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro13:20

Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro

Published on: July 17, 2018

10.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K